Divarasib plus pembrolizumab for KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer is advanced or metastatic and cannot be removed by surgery or treated with radiation alone.
- You have a specific mutation called KRAS G12C in your tumor.
- You have not had any prior chemotherapy or other systemic treatment for advanced lung cancer.
- You are in generally good health (able to care for yourself and up and about more than 50% of the day).
- You have at least one tumor that can be measured on scans.
- You have not had any other cancer in the last 5 years, except for certain low-risk types.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
This program provides access to an investigational drug called divarasib for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It is for those whose cancer has grown after prior treatments, and it aims to see if the drug can help control the disease.
This study tests whether a drug called divarasib can help prevent lung cancer from coming back after surgery and initial treatment. You would only qualify if your cancer has a specific genetic mutation (KRAS G12C) and you've already had surgery and chemotherapy with immunotherapy.
This trial tests a combination of two drugs (pembrolizumab and calderasib) after surgery for people with a specific type of lung cancer gene mutation called KRAS G12C. It aims to see if this therapy can help prevent the cancer from coming back.
This trial tests whether adding a new drug (zoldonrasib) to standard chemotherapy and immunotherapy can help people with a specific type of lung cancer. It is for those with a RAS G12D mutation and no prior treatment for metastatic disease.
This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.